Loading clinical trials...

L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function | Clinical Trials | Clareo Health

COMPLETEDPHASE4

L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function

Effects of Oral Chronic L-arginine Supplementation on Exercise and Renal Function of Heart Transplant Recipients

NCT00213915•University Hospital, Strasbourg, France

View on ClinicalTrials.gov

Summary

* exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction * cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal model by L-arginine supplementation * to determine the potential beneficial effect of L-arginine supplementation on exercise capacity and renal function of heart transplant recipients

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male (\> 18 years old) stable heart transplant recipient for at least 6 weeks
•Stable treatment for at least 3 months
•Sedentary people

Exclusion Criteria

•Unstable cardiac pathology
•Obesity (IMC \> 40)
•Participation in another study in the last month
•Chronic renal failure (creatinine clearance \< 20 ml/min)
•Renal transplantation
•Diabetes
•Impossibility to practice exercise test
•Nitrate therapy

Locations (3)

Institut de Physiologie

Strasbourg, France

Service de Chirurgie Vasculaire

Strasbourg, France

Service des Explorations Fonctionnelles Respiratoires et de l'Exercice

Strasbourg, France

Key Dates

Start Date

February 1, 2004

Completion Date

December 1, 2004

Last Updated

December 22, 2025

Enrollment

Estimated participants

Conditions

Heart Transplantation

Interventions

12 g of L-arginine glutamate during 6 weeks twice a day

DRUG

Multimodal Analysis of Endomyocardial Biopsies

NCT07359690

Heart TransplantationDilated Cardiomyopathy (DCM)+5 more

View study

RECRUITING

Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation

NCT07291258

Solid Organ TransplantationPregnancy+11 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function

Inclusion Criteria

Exclusion Criteria

Multimodal Analysis of Endomyocardial Biopsies

Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation

Haemoadsorption During Heart Transplantation

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation

Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients